Resistance of K562 Leukaemia Cells to Etoposide
Author Information
Author(s): M.K. Ritkel, D. Roberts, W.P. Allan, J. Raymond, V.V. Bergoltz, J.C. Yalowich
Primary Institution: University of Pittsburgh School of Medicine
Hypothesis
Resistance to VP-16 in K562 cells is associated with changes in topoisomerase II.
Conclusion
K/VP.5 cells show reduced topoisomerase II levels and altered drug-induced DNA damage response compared to K562 cells.
Supporting Evidence
- K/VP.5 cells were 30-fold resistant to VP-16 compared to K562 cells.
- Topoisomerase II protein levels were reduced 3- to 7-fold in K/VP.5 cells.
- VP-16-induced DNA damage was less in K/VP.5 cells than in K562 cells.
- ATP enhanced VP-16-induced DNA damage more in K562 than in K/VP.5 cells.
Takeaway
Some cancer cells can become resistant to a drug called VP-16, and this study found that the reason is changes in a protein that helps manage DNA.
Methodology
K562 leukaemia cells were exposed to etoposide to select for resistant clones, and various assays were performed to measure drug response and topoisomerase II activity.
Limitations
The study primarily focuses on a single cell line and may not generalize to other types of cancer cells.
Statistical Information
P-Value
0.002
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website